Skip to main content

No Objective Improvement Seen in Cognitive Function With Exercise During Chemo

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 22, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Oct. 22, 2024 -- Aerobic exercise does not result in differences in objective cognitive function after chemotherapy completion among women with breast cancer, according to a study published online Oct. 21 in Cancer.

Jennifer Brunet, Ph.D., from the University of Ottawa in Ontario, Canada, and colleagues examined the effects of an aerobic exercise intervention initiated during chemotherapy versus usual care on objectively measured cognitive function and self‐reported cognitive function and on the impact of cognitive impairment on quality of life postintervention in a two-arm, two-center randomized control trial. A total of 57 women with stage I to III breast cancer and awaiting chemotherapy were randomly assigned to receive aerobic exercise initiated with chemotherapy or usual care during chemotherapy and aerobic exercise initiated after completion of chemotherapy (28 and 29 women, respectively). The intervention lasted 12 to 24 weeks and included supervised aerobic training and exercise at home.

The researchers found that after accounting for multiple testing, there were no significant differences between the groups in objective cognitive function outcomes postintervention. Significant differences favoring the aerobic exercise group were seen in four of six self-reported cognitive function outcomes.

"In conclusion, among women initiating chemotherapy for breast cancer, an aerobic exercise intervention offered during chemotherapy did not result in significant differences in objective cognitive function after chemotherapy completion in comparison to usual care," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Epilepsy More Common With Frontotemporal Dementia

TUESDAY, June 10, 2025 -- Epilepsy is more common among those with frontotemporal dementia (FTD) than among people with Alzheimer disease (AD) or healthy controls, according to a...

American Society of Clinical Oncology, May 31-June 3

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians...

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer

MONDAY, June 9, 2025 -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.